Key result
Losartan and captopril reduced heart weight and LV wall thickness in mice with viral myocarditis, but losartan did not influence myocardial necrosis and inflammation.
Why the study?
Does losartan improve myocarditis, acute heart failure, and LV hypertrophy compared to captopril and enalapril in mice with viral myocarditis?
Does losartan improve myocarditis, acute heart failure, and LV hypertrophy compared to captopril and enalapril in mice with viral myocarditis?
In a murine model of viral myocarditis, angiotensin II receptor blockade with losartan improved signs of heart failure and LV hypertrophy but did not reduce viral-evoked myocardial inflammation and necrosis, unlike captopril.
Answers are grounded in this paper and cite their sources.
Losartan may reduce LV hypertrophy without anti-inflammatory effects in murine myocarditis; leaves open differential ARB-ACEI remodeling effects in patients.
Losartan, a recently developed nonpeptide angiotensin II (AII) receptor antagonist, was orally administered for 14 days to mice with viral myocarditis, beginning 7 days after encephalomyocarditis virus inoculation. The angiotensin-converting enzyme inhibitors (ACEI) captopril and enalapril were also administered in the same manner to compare the therapeutic effects of these three drugs on the degree of myocarditis, acute heart failure, and left ventricular (LV) hypertrophy. Heart weight and the heart weight/body weight ratio were reduced by losartan (60 mg/kg/day) and captopril (7.5 mg/kg/day), but not by enalapril (1 mg/kg/day). LV wall thickness and cavity dimension were decreased in the losartan and captopril groups. Captopril reduced both myocardial necrosis and inflammation, whereas enalapril reduced myocardial necrosis but not inflammation. However, none of the studied losartan doses (1.2, 12, 60 mg/kg/day) influenced myocardial necrosis and inflammation resulting from viral infection. Thus, specific blockade of AII is beneficial in congestive heart failure (CHF) and LV hypertrophy but is not effective in viral-evoked inflammation and injury.
No takes yet. Share an insight, caveat, or question.
ARAKI et al. (1995) studied Murine acute myocarditis due to encephalomyocarditis virus. Losartan, captopril, and enalapril vs. Implicit control / each other was evaluated on Degree of myocarditis, acute heart failure, and left ventricular (LV) hypertrophy. Losartan and captopril reduced heart weight and LV wall thickness in mice with viral myocarditis, but losartan did not influence myocardial necrosis and inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: